Intra-Cellular Therapies (ITCI) Tops Q3 EPS by 21c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/16/2024
- Wall Street stocks mixed on higher Treasury yields, rate expectations
- Powell says recent inflation data point to need to keep rates higher for longer
- UnitedHealth (UNH) beats earnings, revenue estimates in Q1; shares up
- Bank of America profit hurt by losses on credit cards, office loans
- Morgan Stanley (MS) earnings beat lifts stock
- Trump Media & Technology Group (DJT) Files S-1
- Tesla (TSLA) Senior VP Drew Baglino Is Said To Leave The Company - Bloomberg
- GE HealthCare (GEHC) Announces Resignation of Jan Makela, CEO of Imaging
- General Motors (GM) Said to be Moving Detroit HQ to Dan Gilbert's Hudson Tower - Bloomberg
- Biohaven Pharma (BHVN) presents update on degrader platform and summary of progress to date in Phase 1 single ascending dose study for BHV-1300
- Midday movers: Morgan Stanley, UnitedHealth rise; Tesla falls
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
- After-hours movers: Tesla, Gildan Activewear, Macatawa Bank, and more
- Midday movers: Goldman Sachs and Meta Platforms rise; Apple and Tesla fall
- Nike, Alpine Immune Sciences rise premarket; CarMax, Robinhood and Regeneron fall
Intra-Cellular Therapies Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 9, 2020 7:30 AM ESTPositive topline results reported from Study 402, a Phase 3 Study evaluating lumateperone as an adjunctive treatment to lithium or valproate in patients with bipolar depression.
Company is preparing sNDA for the treatment of bipolar depression for submission to the FDA. Study 402, in conjunction with our previously reported positive Phase 3 monotherapy study, Study 404, forms the basis for our sNDA.
Strong CAPLYTA commercial performance with week-over-week and quarter-over-quarter prescription growth despite COVID-19... More
